Analytical Data
-
Gene name
HIN-1/SCGB3A1
- Application
-
Alternative Names
HIN1; HIN-1; LU105; PnSP-2; UGRP2; Cytokine High In Normal-1; Pneumo Secretory Protein 2; High in normal 1; Uteroglobin-related protein 2
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q96QR1
-
Expression Region
Phe21~Gly104
-
Molecular Weight
38kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HIN-1, a protein originally identified in the context of breast cancer, is a member of the secretoglobin family and serves as a potential biomarker for various cancer types. Research has indicated that HIN-1 expression may be suppressed during tumorigenesis, particularly in the breast and other epithelial cancers, making it a candidate for both diagnostic and therapeutic applications. The SCGB3A1 gene, closely related to HIN-1, encodes a secreted protein that is also implicated in tumor biology. Studies have shown that recombinant HIN-1/SCGB3A1 proteins can elicit immune responses, suggesting their potential as vaccine candidates or targets for immune modulation in cancer therapy. Understanding the structural and functional properties of these recombinant proteins is crucial for elucidating their roles in tumor biology and for developing novel therapeutic strategies. By investigating the interactions between HIN-1/SCGB3A1 and the immune system, researchers aim to enhance our knowledge of cancer progression and identify new avenues for treatment, ultimately improving patient outcomes in oncology.
